Polypeptide Analysis via Mixed-Mode SPE and LC-MS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for analyzing polypeptides, such as ligand binding assays (LBAs) and liquid chromatography tandem mass spectroscopy (LC-MS/MS), face challenges including low sensitivity, non-specific binding, and difficulty in distinguishing similar molecules like analogs and metabolites, especially for intact polypeptides with multiple disulfide bonds like insulin.
Innovation Solution
The use of multi-step mixed-mode solid phase extraction combined with liquid chromatography column chemistry featuring a hydrophobic surface group and ionizable modifiers, coupled with high sensitivity mass spectroscopy, specifically triple quadrupole MS, to produce specific polypeptide fragments and improve selectivity and sensitivity for polypeptide analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If ligand binding assays (ELISA) are used to analyze polypeptides, then the analysis can be performed with available antibodies, but the method lacks specificity and accuracy due to cross reactivity and inability to distinguish similar molecules
Solution Approach 1:
The patent replaces the biological recognition mechanism of ELISA (antibody-antigen binding) with a physical separation and detection mechanism using liquid chromatography and mass spectrometry. The LC-MS/MS system separates polypeptides based on their physical and chemical properties (hydrophobicity, charge, size) and detects them through mass-to-charge ratio, eliminating the need for specific antibodies and avoiding cross-reactivity issues inherent in immunoassays.
Solution Approach 2:
The patent utilizes changes in physical and chemical parameters during the analysis process. The polypeptide sequence is modified through enzymatic digestion (e.g., trypsin treatment) to generate characteristic fragments, and the chromatographic conditions are adjusted (mobile phase composition, flow rate, temperature) to optimize separation. Mass spectrometry parameters such as collision energy and quadrupole settings are tuned to enhance detection specificity for particular mass-to-charge ratios, thereby improving measurement precision without requiring complex antibody-based systems.
2Measurement precision
If liquid chromatography tandem mass spectroscopy (LC-MS/MS) is used to analyze intact polypeptides, then the method provides better specificity, but sensitivity is low due to poor transfer into gas phase and poor fragmentation from stabilizing disulfide bonds
Solution Approach 1:
The patent applies segmentation by dividing the intact polypeptide into smaller peptide fragments through enzymatic digestion (e.g., using trypsin to cleave at lysine or arginine residues). This fragmentation reduces the molecular size and complexity, improving the transfer efficiency into the gas phase and enhancing fragmentation patterns in the mass spectrometer. The resulting smaller peptides exhibit better ionization characteristics and more characteristic mass spectra, thereby improving sensitivity while maintaining the specificity provided by LC-MS/MS.
Solution Approach 2:
The patent optimizes several parameters to improve sensitivity: the mobile phase composition is adjusted to enhance polypeptide solubility and ionization efficiency; the mass spectrometry collision energy is tuned to produce characteristic fragments while minimizing degradation; the quadrupole mass filter settings are optimized to select specific mass-to-charge ratios with high sensitivity. These parameter optimizations enable reliable detection of polypeptides even at low concentrations, resolving the sensitivity issue while preserving the specificity advantage of LC-MS/MS.
3Device complexity
If conventional liquid chromatography is used for polypeptide analysis, then the method is simpler, but non-specific binding and poor solubility make method development difficult
Solution Approach 1:
The patent employs parameter changes in the mobile phase composition to address solubility and binding issues. The mobile phase includes buffered solutions with controlled pH and ionic strength, along with organic modifiers (e.g., acetonitrile, methanol) in optimized concentrations. These parameter adjustments enhance polypeptide solubility by reducing non-specific interactions with the chromatographic stationary phase and improve peak shape and detection. The use of ionizable modifiers in the mobile phase also helps maintain polypeptide charge states, preventing aggregation and improving overall reliability of the analysis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the selectivity and sensitivity of polypeptide analysis, allowing for the detection of low abundance peptides and reducing endogenous background, achieving a detection limit of 0.25 ng/mL or less in a 250 microliter specimen, and effectively differentiating between related compounds like insulin glargine, detemir, and glulisine.
Implementation Method 1
treating a specimen suspected of including a polypeptide with a base and extracting a first fraction of the treated specimen by solid phase extraction
Implementation Method 2
separating a component of the first fraction by liquid chromatography using a chromatographic surface including a hydrophobic surface group and one or more ionizable modifiers
Implementation Method 3
separating a component of the first fraction by liquid chromatography using a chromatographic surface including a hydrophobic surface group and one or more ionizable modifiers
Implementation Method 4
analyzing the component of the first fraction by mass spectroscopy, thereby identifying the polypeptide, if present, using a signal corresponding to a transition from a multiply charged precursor to a sequence fragment ion
Data Source
AI summary
A method for identifying a polypeptide a specimen can include (i) treating a specimen suspected of including an insulin with a base; (ii) extracting a first fraction of the treated specimen by solid phase extraction using a mixed mode or polymeric reversed-phase media and a first solvent including an acid; (iii) separating a component of the first fraction by liquid chromatography using a chromatographic surface including a hydrophobic surface group and one or more ionizable modifiers, and a second solvent including an acid; and (iv) analyzing the component of the first fraction by mass spectroscopy, thereby identifying the polypeptide, if present, using a signal corresponding to a sequence fragment ion from the polypeptide. The signal can correspond to an intact multiply charged precursor fragment selected in a first quadrupole and its corresponding sequence fragment ion selected in a final quadrupole.